$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

$regn Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000180422022000015 Filed on May 04, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$2.965B	$2.529B
YoY Change	17.26%	38.32%
Cost Of Revenue	$404.9M	$308.0M
YoY Change	31.46%	41.74%
Gross Profit	$2.560B	$2.221B
YoY Change	15.29%	37.85%
Gross Profit Margin	86.34%	87.82%
Selling, General & Admin	$450.0M	$405.6M
YoY Change	10.95%	10.43%
% of Gross Profit	17.58%	18.26%
Research & Development	$843.8M	$742.9M
YoY Change	13.58%	27.23%
% of Gross Profit	32.96%	33.45%
Depreciation & Amortization	$74.30M	$67.40M
YoY Change	10.24%	20.14%
% of Gross Profit	2.9%	3.04%
Operating Expenses	$1.294B	$1.149B
YoY Change	12.65%	20.74%
Operating Profit	$1.259B	$1.113B
YoY Change	13.1%	58.93%
Interest Expense	$13.60M	$14.60M
YoY Change	-6.85%	139.34%
% of Operating Profit	1.08%	1.31%
Other Income/Expense, Net	-$197.4M	$140.3M
YoY Change	-240.7%	-545.4%
Pretax Income	$1.061B	$1.253B
YoY Change	-15.32%	87.41%
Income Tax	$87.60M	$137.8M
% Of Pretax Income	8.26%	11.0%
Net Earnings	$973.5M	$1.115B
YoY Change	-12.71%	78.55%
Net Earnings / Revenue	32.83%	44.1%
Basic Earnings Per Share	$9.12	$10.58
Diluted Earnings Per Share	$8.61	$10.09
COMMON SHARES
Basic Shares Outstanding	106.8M shares	105.4M shares
Diluted Shares Outstanding	113.1M shares	110.5M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.051B	$3.504B
YoY Change	101.22%	-12.47%
Cash & Equivalents	$3.346B	$1.438B
Short-Term Investments	$3.705B	$2.066B
Other Short-Term Assets	$424.9M	$713.0M
YoY Change	-40.41%	0.71%
Inventory	$1.992B	$2.165B
Prepaid Expenses
Receivables	$4.839B	$4.173B
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$14.31B	$10.06B
YoY Change	42.28%	16.32%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.556B	$3.263B
YoY Change	9.01%	10.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$7.131B	$3.584B
YoY Change	98.96%	8.87%
Other Assets	$262.0M	$145.7M
YoY Change	79.82%	-9.62%
Total Long-Term Assets	$12.04B	$7.717B
YoY Change	56.05%	8.49%
TOTAL ASSETS
Total Short-Term Assets	$14.31B	$10.06B
Total Long-Term Assets	$12.04B	$7.717B
Total Assets	$26.35B	$17.77B
YoY Change	48.26%	12.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$470.3M	$543.0M
YoY Change	-13.39%	56.03%
Accrued Expenses	$2.046B	$1.492B
YoY Change	37.13%	30.53%
Deferred Revenue	$491.3M	$464.9M
YoY Change	5.68%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$718.0M
YoY Change	-100.0%
Total Short-Term Liabilities	$3.008B	$3.218B
YoY Change	-6.53%	56.57%
LONG-TERM LIABILITIES
Long-Term Debt	$1.980B	$1.979B
YoY Change	0.08%	176.77%
Other Long-Term Liabilities	$692.5M	$571.5M
YoY Change	21.17%	77.76%
Total Long-Term Liabilities	$2.673B	$2.550B
YoY Change	4.8%	693.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.008B	$3.218B
Total Long-Term Liabilities	$2.673B	$2.550B
Total Liabilities	$6.434B	$5.795B
YoY Change	11.02%	59.89%
SHAREHOLDERS EQUITY
Retained Earnings	$19.94B	$12.01B
YoY Change	66.07%	50.02%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$8.611B	$6.935B
YoY Change	24.16%	545.87%
Treasury Stock Shares	19.94M shares	17.10M shares
Shareholders Equity	$19.91B	$11.98B
YoY Change
Total Liabilities & Shareholders Equity	$26.35B	$17.77B
YoY Change	48.26%	12.79%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	$973.5M	$1.115B
YoY Change	-12.71%	78.55%
Depreciation, Depletion And Amortization	$74.30M	$67.40M
YoY Change	10.24%	20.14%
Cash From Operating Activities	$2.102B	$668.5M
YoY Change	214.39%	-4.23%
INVESTING ACTIVITIES
Capital Expenditures	-$141.8M	-$115.3M
YoY Change	22.98%	-32.22%
Acquisitions
YoY Change
Other Investing Activities	-$1.564B	-$943.7M
YoY Change	65.68%	245.55%
Cash From Investing Activities	-$1.705B	-$1.059B
YoY Change	61.03%	138.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	-$163.5M	$211.9M
YoY Change	-177.16%	-143.18%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$64.70M	-$366.4M
YoY Change	-117.66%	-209.18%
NET CHANGE
Cash From Operating Activities	$2.102B	$668.5M
Cash From Investing Activities	-$1.705B	-$1.059B
Cash From Financing Activities	$64.70M	-$366.4M
Net Change In Cash	$461.1M	-$756.9M
YoY Change	-160.92%	-228.2%
FREE CASH FLOW
Cash From Operating Activities	$2.102B	$668.5M
Capital Expenditures	-$141.8M	-$115.3M
Free Cash Flow	$2.244B	$783.8M
YoY Change	186.23%	-9.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000872589
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	0-19034
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	REGENERON PHARMACEUTICALS, INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NY
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	13-3444607
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	777 Old Saw Mill River Road
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Tarrytown
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10591-6707
CY2022Q1	dei	City Area Code CityAreaCode	914
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	847-7000
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock - par value $.001 per share
CY2022Q1	dei	Trading Symbol TradingSymbol	REGN
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3345700000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2885600000	USD
CY2022Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	3704900000	USD
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2809100000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4839000000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6036500000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	1991500000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	1951300000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	424900000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	332400000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	14306000000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	14014900000	USD
CY2022Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	7084000000	USD
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	6838000000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3556400000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3482200000	USD
CY2022Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1140300000	USD
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	876900000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	262000000.0	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	222800000	USD
CY2022Q1	us-gaap	Assets Assets	26348700000	USD
CY2021Q4	us-gaap	Assets Assets	25434800000	USD
CY2022Q1	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	470300000	USD
CY2021Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	564000000.0	USD
CY2022Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2046000000	USD
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2206800000	USD
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	USD
CY2022Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	19940149	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	19392961	shares
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue	8611200000	USD
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	8260900000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	19914700000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	18768800000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26348700000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25434800000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2965100000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2528700000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	843800000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	742900000	USD
CY2022Q1	regn	Acquired In Process Research And Development AcquiredInProcessResearchAndDevelopment	28100000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	719700000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	491300000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	442000000.0	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3007600000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3932500000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1980400000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1980000000	USD
CY2022Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	720000000.0	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	33500000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	73300000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	692500000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	680200000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	6434000000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	6666000000	USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	8754100000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	8087500000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	19941800000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	18968300000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-170100000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-26200000	USD
CY2021Q1	regn	Acquired In Process Research And Development AcquiredInProcessResearchAndDevelopment	0	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	450000000.0	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	405600000	USD
CY2022Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	20200000	USD
CY2021Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	40500000	USD
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	1706600000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	1416000000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	1258500000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	1112700000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-183800000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	154900000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	13600000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	14600000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-197400000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	140300000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1061100000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1253000000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	87600000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	137800000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	973500000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	1115200000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	9.12
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	10.58
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	8.61
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	10.09
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106800000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105400000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	113100000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	110500000	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	973500000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	1115200000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-144900000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-13300000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	1000000.0	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	200000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	829600000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1102100000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	18768800000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	593700000	USD
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	105800000	USD
CY2022Q1	regn	Stock Issued Distributed During Period Value Employee Benefit Plan StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan	14500000	USD
CY2022Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	352000000.0	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	165900000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	973500000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-143900000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	19914700000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	11025300000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	93900000	USD
CY2021Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	66400000	USD
CY2021Q1	regn	Stock Issued Distributed During Period Value Employee Benefit Plan StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan	10000000.0	USD
CY2021Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	323500000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	135600000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	1115200000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-13100000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	11977000000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	973500000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	1115200000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	74300000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	67400000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	166900000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	130900000	USD
CY2022Q1	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-204500000	USD
CY2021Q1	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	144400000	USD
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-84300000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-28700000	USD
CY2022Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	225000000.0	USD
CY2021Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-10100000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1197500000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	58300000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	88600000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	252800000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	44800000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	50000000.0	USD
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	9500000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-143600000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-250400000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-34700000	USD
CY2022Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1128200000	USD
CY2021Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-446700000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2101700000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	668500000	USD
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2309800000	USD
CY2021Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1360000000	USD
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	746300000	USD
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	416300000	USD
CY2022Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	141800000	USD
CY2021Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	115300000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1705300000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1059000000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	521600000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	95000000.0	USD
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	98800000	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	154500000	USD
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	358100000	USD
CY2021Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	306900000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	64700000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-366400000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	461100000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-756900000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2898100000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2207300000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3359200000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1450400000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	973500000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	1115200000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106800000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	105400000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	113100000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	110500000	shares
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	9.12
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	10.58
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	8.61
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	10.09
CY2022Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	9965100000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1300000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	216200000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	9750200000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	8428700000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	10800000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	42300000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	8397200000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	3704900000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	2809100000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	6045300000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	5588100000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	9750200000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	8397200000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	8674900000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	202900000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	214100000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	13300000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	8889000000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	216200000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	6516300000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	42300000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	6516300000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	42300000	USD
CY2022Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2021Q1	regn	Marketable Securities Realized Gain MarketableSecuritiesRealizedGain	0	USD
CY2021Q1	regn	Marketable Securities Realized Loss MarketableSecuritiesRealizedLoss	0	USD
CY2022Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-211200000	USD
CY2021Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	143900000	USD
CY2022Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	46700000	USD
CY2021Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	40000000	USD
CY2022Q1	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	1686000000	USD
CY2021Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	1887000000	USD
CY2022Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	773500000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	721900000	USD
CY2022Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	644900000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	707200000	USD
CY2022Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	47300000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	73700000	USD
CY2022Q1	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	525800000	USD
CY2021Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	448500000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	1991500000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	1951300000	USD
CY2022Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	566500000	USD
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	510000000	USD
CY2022Q1	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P5Y
CY2022Q1	us-gaap	Lessee Finance Lease Option To Extend LesseeFinanceLeaseOptionToExtend	five-year
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.083
CY2021Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.110
CY2022Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	566973	shares
CY2022Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	352000000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3345700000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1437900000	USD
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	13500000	USD
CY2021Q1	us-gaap	Restricted Cash RestrictedCash	12500000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3359200000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1450400000	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	80700000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	74800000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	75600000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	83600000	USD

Files In Submission

Name	View Source	Status
0001804220-22-000015-index-headers.html	Edgar Link	pending
0001804220-22-000015-index.html	Edgar Link	pending
0001804220-22-000015.txt	Edgar Link	pending
0001804220-22-000015-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_01a.jpg	Edgar Link	pending
image_0a.jpg	Edgar Link	pending
image_1a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
regn-20220331.htm	Edgar Link	pending
regn-20220331.xsd	Edgar Link	pending
regn-20220331_cal.xml	Edgar Link	unprocessable
regn-20220331_def.xml	Edgar Link	unprocessable
regn-20220331_htm.xml	Edgar Link	completed
regn-20220331_lab.xml	Edgar Link	unprocessable
regn-20220331_pre.xml	Edgar Link	unprocessable
regn-ex_104x3312022x10q.htm	Edgar Link	pending
regn-ex_105x3312022x10q.htm	Edgar Link	pending
regn-ex_106x3312022x10q.htm	Edgar Link	pending
regn-ex_311x03312022x10q.htm	Edgar Link	pending
regn-ex_312x03312022x10q.htm	Edgar Link	pending
regn-ex_32x03312022x10q.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

2022 Q1 Form 10-Q Financial Statement

#000180422022000015 Filed on May 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN REGENERON PHARMACEUTICALS, INC. Stock $regn

2022 Q1 Form 10-Q Financial Statement

#000180422022000015 Filed on May 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn